United States Heart Pump Device Market Size & Outlook, 2025-2033
United States Heart Pump Device Market Insights
- Based on Reed Intelligence findings, the United States Heart Pump Device Market reached USD 359.16 Million in 2024 and is estimated to attain USD 2159.21 Million by 2033.
- From 2026 to 2033, the United States market is expected to grow at a steady CAGR of 22.22%.
- Within the By Product category, Intra-Aortic Balloon Pumps dominated in 2024 in terms of market size contribution.
- Over the forecast period, Ventricular Assist Devices is forecasted to deliver the fastest growth, positioning it as the most lucrative By Product segment.
![United States Heart Pump Device Market Size, Share & Growth Report By [2033]](https://reedintelligence.com/uploads/charts/united-states-heart-pump-device-market-united-states-by-product-34269.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- United States contributed 21% to the global Heart Pump Device Market size in 2024.
- By 2033, United States is forecasted to remain the largest global market for Heart Pump Device Market.
- In North America, United States is projected to capture the leading share of market size by 2033.
- Among North America markets, United States is expected to post the fastest growth, reaching USD 2185.53 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 359.16 Million |
| Market Size In 2033 | USD 2159.21 Million |
| Largest segment | Intra-Aortic Balloon Pumps |
| Units | Revenue in USD Million |
| CAGR | 22.22% (2025-2033) |
| Segmnetation Covered | |
| By Product |
|
| By Type |
|
| By Therapy |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Heart Pump Device Market By Product 2025-2033 (USD Million)
| By Product | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intra-Aortic Balloon Pumps | XX.x | XX.x | XX.x | 188.34 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ventricular Assist Devices | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total Artificial Heart | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Heart Pump Device Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Implantable Heart Pump Devices | XX.x | XX.x | XX.x | 198.32 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Extracorporeal Heart Pump Devices | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Heart Pump Device Market By Therapy 2025-2033 (USD Million)
| By Therapy | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bridge-to-transplant (BTT) | XX.x | XX.x | XX.x | 144.38 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Bridge-to-candidacy (BTC) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Destination Therapy (DT) | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Therapies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.